# Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting

> **NCT00787566** · PHASE2 · COMPLETED · sponsor: **Shin Nippon Biomedical Laboratories, Ltd.** · enrollment: 68 (actual)

## Conditions studied

- Chemotherapy-Induced Nausea and Vomiting

## Interventions

- **DRUG:** Intranasal granisetron

## Key facts

- **NCT ID:** NCT00787566
- **Lead sponsor:** Shin Nippon Biomedical Laboratories, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2009-04
- **Final completion:** 2009-05
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2011-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00787566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00787566, "Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00787566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*